Table 6. Comparison between MCPyV-positive and negative cases.
| MARKERS | TOTAL | MCPyV POSITIVE | MCPyV NEGATIVE | SIGNIFICANCE | |
|---|---|---|---|---|---|
| Morphology | Combined histology Pure MCC N:124 | Combined: 19 (15.3%) | 2 (2.9%) | 17 (31.8%) | P<0.001, Chi2:19.25 |
| Pure MCC: 105 (84.7%) | 68 (97.1%) | 37 (68.5%) | |||
| Lymphoid infiltration N:127 | Low: 53(41.7%) | 23(32.4%) | 30(53.6%) | P:0.013, Chi2: 8.64 | |
| Intermediate: 41(32.3%) | 23(32.3%) | 18(32.1%) | |||
| High: 33 (26%) | 25(35.2%) | 8 (14.3%) | |||
| UIceration N:124 | Presence: 26 (21%) | 4 (5.9%) | 22 (39.3%) | P<0.001, Chi2:20.68 | |
| Absence: 98 (79%) | 64(94.1%) | 34 (60.7%) | |||
| Elastosis N:118 | Presence 65 (55.1%) | 27(41.5%) | 38 (71.7%) | P:0.001, Chi2: 10.73 | |
| Absence: 53 (44.9%) | 38(58.5%) | 15 (28.3%) | |||
| IHC neoplastic cells | CK20 N:172 | Positive: 146(84.8%) | 92(93.9%) | 54(73%) | P<0.001, Chi2: 14.36 |
| Negative/Low: 26 (15.1%) | 6 (6.1%) | 20(27.0%) | |||
| P53 N:171 | High: 38(22.2%) | 4(4.1%) | 34(45.9%) | P<0.001, Chi2: 42.48 | |
| Negative/Low: 133(77.8%) | 93(95.9%) | 40(54.0%) | |||
| Ki67 N:132 | High: 35(26.5%) | 12(15.4%) | 23(42.6%) | P<0.001, Chi2: 12.12 | |
| Intermediate: 97 (73.5%) | 66(84.6%) | 31(57.4%) | |||
| Chromogranin N:171 | High: 105(61.4%) | 71(71.7%) | 34(47.2%) | P<0.001, Chi2: 18.32 | |
| Negative/Low: 19 (11.1%) | 3 (3%) | 16(22.2%) | |||
| Intermediate: 47 (27.5%) | 25(25.2%) | 22(30.6%) | |||
| Synaptophysin N:152 | High: 118(77.6%) | 80(88.9%) | 38(61.3%) | P<0.001, Chi2: 16.15 | |
| Negative/Low: 6 (4%) | 2(2.2%) | 4(6.4%) | |||
| Intermediate: 28 (18.4%) | 8 (8.9%) | 20(32.3%) | |||
| ALK N:169 | High: 113(68.5%) | 79(83.2%) | 34(48.6%) | P<0.001; Chi2: 24.96 | |
| Negative/Low: 15 (9.1%) | 2 (2.1%) | 13(18.6%) | |||
| Intermediate 37(22.4%) | 14(14.7%) | 23(32.9%) | |||
| EZH2 N:166 | High: 151(91%) | 90(95.7%) | 61(84.7%) | P:0.014; Chi2: 8.47 | |
| Negative/Low: 3 (1.8%) | 2 (2.1%) | 1(1.4%) | |||
| Intermediate: 12 (7.2%) | 2 (2.1%) | 10(13.9%) | |||
| HLA-I N:166 | High: 44(26.2%) | 13(13.7%) | 31(42.5%) | p<0.001; Chi2: 25.04 | |
| Negative/Low: 72(42.9%) | 55(57.9%) | 17(23.3%) | |||
| Intermediate: 52(30.9%) | 27(28.4%) | 25(34.2%) | |||
| Active Caspase 3 N:127 | High: 82(64.6%) | 57(79.2%) | 25(45.4%) | P<0.001; Chi2: 18.62 | |
| Negative/Low: 6(4.7%) | 0 (0.0%) | 6(10.9%) | |||
| Intermediate: 39(30.7%) | 15(20.8%) | 24(43.6%) | |||
| PAX5 N:171 | High: 103(60.2%) | 74(75.5%) | 29(39.7%) | P<0.001; Chi2: 22.37 | |
| Negative/Low: 68(39.8%) | 24(24.5%) | 44(60.3%) | |||
| CD56 N:169 | High: 105 (62.1%) | 64(66.7%) | 41(56.2%) | P:0.025; Chi2: 7.36 | |
| Negative/Low: 25 (14.8%) | 8(8.3%) | 17(23.3%) | |||
| Intermediate: 39 (23.1%) | 24(25%) | 15(20.6%) | |||
| IHC Tumour stroma | CD3 N:169 | High: 48 (28.4%) | 39(40.6%) | 9(12.3%) | P<0.001; Chi2: 16.33 |
| Negative/low: 62 (36.7%) | 29(30.2%) | 33(45.2%) | |||
| Intermediate: 59 (34.9%) | 28(29.2%) | 31(42.5%) | |||
| CD4 N:172 | High: 93 (54.1%) | 63(64.3%) | 30(40.5%) | P:0.002; Chi2: 9.57 | |
| Negative/low: 79(45.9%) | 35(25.7%) | 44(59.5%) | |||
| CD20 N:169 | High: 46(27.2%) | 38(39.6%) | 8(11%) | P<0.001; Chi2: 17.15 | |
| Low: 123(72.8%) | 58(60.4%) | 65(89%) | |||
| FOXP3 N:165 | High: 73 (44.2%) | 54(56.8%) | 19(27.1%) | P:0.001; Chi2: 14.46 | |
| Negative/Low 87 (52.7%) | 39(41%) | 48(68.6%) | |||
| Intermediate: 5 (3%) | 2(2.1%) | 3(4.3%) | |||
| ROR gamma N:168 | High: 22(13.1%) | 15(15.5%) | 7(9.9%) | P:0.04; Chi2: 6.4533 | |
| Negative/Low: 142(84.5%) | 82(84.5%) | 60(84.5%) | |||
| Intermediate: 4(2.4%) | 0 (0%) | 4(2.4%) | |||
| PD1 N:167 | High: 78(46.7%) | 52(55.9%) | 41(44.1%) | P:0.008; Chi2: 7.15 | |
| Negative/Low: 89(53.3%) | 26(35.1%) | 48(64.9%) | |||
| CD8 N: 169 | High: 108(63.9%) | 67(69.8%) | 29(30.2%) | P:0.068; Chi2: 3.34 | |
| Negative/Low: 61(36.1%) | 29(30.2%) | 32(43.8%) | |||
| CD68 N:169 | High: 46(27.2%) | 36(37.1%) | 10(13.9%) | P:0.001; Chi2: 18.62 | |
| Negative/Low: 5(3%) | 1 (1%) | 4 (5.6%) | |||
| Intermediate: 118(69.8%) | 60(61.9%) | 58(80.9%) | |||
| Granzyme B N:169 | High: 23 (13.6%) | 18(18.6%) | 5(6.9%) | P<0.001, Chi2:15.24 | |
| Negative/Low: 77(45.6%) | 32(33%) | 45(62.5%) | |||
| Intermediate: 69(40.8%) | 47(48.4%) | 22(30.6%) | |||
| Perforin N:101 | High: 15 (14.8%) | 13(22%) | 2(4.8%) | P:0.014, Chi2:8.56 | |
| Negative/Low: 83(82.2%) | 43(72.9%) | 40(95.2%) | |||
| Intermediate: 3(3%) | 3(5%) | 0 (0%) | |||
| TIA1 N:169 | High: 39(23.1%) | 31(32%) | 8(11.1%) | P<0.001; Chi2: 17.04 | |
| Negative/Low: 39(23.1%) | 13(13.4%) | 26(36.1%) | |||
| Intermediate 91(53.8%) | 53(54.6%) | 38(52.8%) | |||
| PDL1 stroma N: 167 | High: 87(52.1%) | 60(63.8%) | 27(37%) | P:0.001; Chi2: 11.86 | |
| Negative/Low: 80(47.9%) | 34(36.2%) | 46(63%) |